Latest Piperazines Stories
MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Dec. 11, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A.
- Fewer patients on Tasigna vs. Gleevec had their leukemia progress to advanced stage, a key goal of treatment in CML and important clinical benefit (1) EAST HANOVER, N.J., Dec.
SAN FRANCISCO, Dec.
LONDON, Nov. 27, 2014 /PRNewswire/ -- INTRODUCTIONTargeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry.
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
WHIPPANY, N.J., Nov. 24, 2014 /PRNewswire/ -- The U.S.
Study Addresses Key Question Raised in Regulatory Review; Flibanserin New Drug Application to be Resubmitted Q1 2015 RALEIGH, N.C., Nov.
NEW YORK, Nov.
Company plans to commence clinical development of SUBA®-Itraconazole for treatment of basal cell carcinoma in patients with basal cell carcinoma nevus syndrome TAMPA, Fla.